MS-101: Pathogenesis, Diagnostic and Clinical Course Treatment Considerations in MS (A CSPE Core Curriculum Series)

Activity Description

Multiple sclerosis (MS) affects an estimated 400,000 people in the U.S., with approximately 10,000 new cases reported every year. As a chronic and progressive neurologic disease that requires lifelong, dynamic treatment via costly, high-touch medications that also require special handling and storage, multiple sclerosis therapies are often delivered via specialty pharmacy programs. 

The NASP/CSPE MS Core Curriculum Series is intended to increase specialty clinicians’ knowledge of the evolving MS treatment paradigm and provide the necessary professional education to counsel patients and caregivers on the myriad therapeutic options, routes of administration, and behavioral/clinical/financial variables that must be considered alongside drug therapy choices when treating MS across care settings. As the first installment in the four-module NASP/CSPE MS Core Curriculum Series, this activity provides an introduction to MS pathology, epidemiology, and symptom management to specialty pharmacists and nurses.

Learning Objectives

The target audience for this activity includes pharmacists and nurses. Upon completion of this activity, participants will be able to:

  • Describe the basic pathology, epidemiology and demographics of the MS population.
  • Explain the diagnostic process for MS and the principles of the McDonald Criteria.
  • List the four major clinical courses of MS, in particular Relapsing Remitting MS (RRMS) and Secondary Progressive MS (SPMS).
  • Explain the diagnostic category of Clinically Isolated Syndrome (CIS) and be aware of the high risk of MS in this setting.
  • Review symptomatic issues that complicate MS and how best to manage them.

Faculty

Joy Derwenskus, DO, MS
Advanced Neurosciences Institute
Franklin, Tennessee

Heli Hunter, MSN, ACNP, MSCN
Schapiro Center for Multiple Sclerosis
Golden Valley, Minnesota

Steering/Review Committee

Susan Allen, PharmD; Aimee Banks, PharmD; Stephanie LaPointe, PharmD; Brandon Markley, PharmD; Mel Nelson, PharmD; Stacey Ness, PharmD; Libin Philip, PharmD.

Disclosure

It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants the existence of any significant financial interest or any other relationship with the manufacturer of any commercial product(s) discussed in an educational presentation. Joy Derwenskus has served as a Speaker and/or Consultant for EMD Serono, Genzyme, a Sanofi Company, Novartis, and Teva Pharmaceuticals USA. Heli Hunter has served as a Speaker and/or Consultant for Genzyme, a Sanofi Company, Mallinckrodt Pharmaceuticals, Novartis, and Teva Pharmaceuticals USA. Susan Allen, Aimee Banks, Stephanie LaPointe, Brandon Markley, Melissa Nelson, Stacey Ness, and Libin Philip have no relevant commercial and/or financial relationships to disclose.

Please note: The opinions expressed in this activity should not be construed as those of the CME/CE provider. The information and views are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include unlabeled indications. Use of drugs and devices outside of labeling should be considered experimental and participants are advised to consult prescribing information and professional literature.

CE Accreditation

Release Date: 08-09-2018
Expiration Date: 11-02-2019

Pharmacists

This CE activity is jointly provided by ProCE, Inc. and the National Association of Specialty Pharmacy (NASP). ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-18-322-H01-P has been assigned to this knowledge-based, home-study activity. This CE activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers, and is provided at no cost to participants. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.

Nurses

This CE activity is jointly provided by ProCE, Inc. and Wild Iris Medical Education, Inc. This activity provides 1.0 contact hour of nurse CE credit.

Wild Iris Medical Education, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Funding

This activity is supported by educational grants from Bayer, Genzyme, a Sanofi Company, and Novartis.

 

The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Credit Information

Activity Number Credit Amount Accreditation Period
ANCC-Nurses (517) 1 Contact Hour July 31, 2018 - November 02, 2019
0221-9999-18-322-H01-P 1 Contact Hour August 09, 2018 - November 02, 2019